InhibitorSelect p53 Pathway Regulators Panel

A panel containing 18 potent, selective and cell-permeable inhibitors and 1 activator that is useful for the study of p53 pathway:2 mg of ATM Kinase Inhibitor (Cat. No. 118500),5 mg ATM/ATR Kinase Inhibitor (Cat. No. 118501),10 mg of Anacardic Acid (Cat. No. 172050),5 mg of Cdk1 Inhibitor IV, RO-3306 (Cat. No. 217699),5 mg of Casein Kinase II Inhibitor III, TBCA (Cat. No. 218710),1 mg of Chk2 Inhibitor II (Cat. No. 220486),5 mg of Hdm2 E3 Ligase Inhibitor (Cat. No. 373225),5 mg of JNK Inhibitor II (Cat. No. 420119),1 mg of MDM2 Antagonist, Nutlin-3, Racemic (Cat. No. 444143),10 mg of MDMX Inhibitor, SJ-172550 (Cat. No. 444155),5 mg of MG-132 (Cat. No. 474790),5 mg of p21-Activated Kinase Inhibitor III, IPA-3 (Cat. No. 506106),5 mg of Pifithrin-α (Cat. No. 506132),1 mg of PI-103 (Cat. No. 528100),1 mg of PARP Inhibitor VIII, PJ34 (Cat. No. 528150),10 mg of PPM1D Phosphatase Inhibitor (Cat. No. 529578),10 mg of PRIMA-1 (Cat. No. 530050),1 mg of Caspase Inhibitor I (Cat. No. 627610),and 1 mg Trichostatin A, Streptomyces sp. (Cat. No. 647925).Also provided with 15 ml of anhydrous DMSO (Cat. No. KP31817). Supplied with a data sheet.

Packaged under inert gas

Toxicity: Regulatory Review (Z)

Following reconstitution, aliquot and freeze (-20°C). Each solutions is stable for up to 3 months at -20°C.

Please refer to information provided on the CD for reconstitution of individual inhibitors.

Feng, Z. and Levine, A.J., 2010. Trends Cell Biol.20, 427.
Wiman, K.G., 2010. Oncogene29, 4245.
Brown, C.J., et al. 2009. Nat. Rev. Cancer9, 862.
Dey, A., et al. 2008. Br. J. Cancer98, 4.
Levine, A.J., et al. 2006. Cell Death Differ.13, 1027.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany